The potential of PDGFRβ as a predictive biomarker for treatment benefit has first been demonstrated in an IHC-based post hoc analysis of two randomized trials for adjuvant tamoxifen treatment of early breast cancer including either pre- or post-menopausal women [108]. This evidence concerns the gene PDGFRB and breast carcinoma.